Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Facon, Thierry, Kumar, Shaji, Plesner, Torben, Orlowski, Robert Z., Moreau, Philippe, Bahlis, Nizar, Basu, Supratik, Nahi, Hareth +22 more·2019·New England Journal of Medicine

DOI 10.1056/nejmoa1817249

Cited by (1,013)

Items 501–600 of 1,013

Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials
Kwee Yong, Hermann Einsele, Jordan Mark Schecter, Tito Roccia, William M Deraedt, Nikoletta K. Lendvai, Ana Slaughter, Carolina Lonardi, Kaitlyn Connors, Keqin Qi et al. · 2024 · European Journal of Cancer
Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis
Muhammad Osama, Muhammad Haris Khan, Safeena Khan, Amna Hussain, Ammara Tahir, Mehran Ullah, Abdullah Afridi, Ubaid Ullah, Wajeeh Ur Rehman · 2025 · Therapeutic Advances in Hematology
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study
Shinsuke Iida, Takayuki Ishikawa, Chang‐Ki Min, Kihyun Kım, Su Peng Yeh, Saad Z. Usmani, María‐Victoria Mateos, Hareth Nahi, Christoph Johann Heuck, Xiang Qin et al. · 2021 · Annals of Hematology
Patients with multiple myeloma or monoclonal gammopathy of undetermined significance—diagnosis, treatment, and follow-up
Vanessa Piechotta, Nicole Skoetz, Monika Martha Engelhardt, Hermann Einsele, Hartmut Goldschmidt, Christof Scheid · 2022 · Deutsches Ärzteblatt international
Autologous stem cell transplantation in multiple myeloma patients over 70 years: A GIMEMA Lazio Working Group experience in a retrospective case–control study
Angela Rago, Ombretta Annibali, Valeria Tomarchio · 2022 · European Journal Of Haematology
Evidence-based recommendations for induction and maintenance treatment of newly diagnosed transplant-ineligible multiple myeloma patients
Abdul Rafae, Hamid Ehsan, Ahsan Wahab, Sana Irfan Khan, ISRAR AHMAD KHAN, Sara Ashraf, Sundas Ali, Farhan Khalid, Karun Neupane, Jason Neil Valent et al. · 2022 · Critical Reviews in Oncology/Hematology
Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment
Gianfranco Lapietra, Francesca Fazio, Maria Teresa Petrucci · 2022 · Biomolecules
Current Main Topics in Multiple Myeloma
Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Attilio Olivieri, Massimo Offidani · 2023 · Cancers
Limited treatment options in refractory multiple myeloma: promising therapeutic developments
Albert Oriol, Laura Abril, Gladys Ibarra, Alicia Senín · 2019 · Expert Review of Anticancer Therapy
CD38: From Positive to Negative Expression after Daratumumab Treatment
Bonell Patiño-Escobar, Roberto Ramos, Maximo Linares, Angie Mejía, Sebastián Alcalá · 2020 · Cureus
Outcomes of lenalidomide‐ or bortezomib‐based regimens in older patients with plasma cell myeloma
Peter M. Barth, Smith Giri, John Leonard Reagan, Adam J. Olszewski · 2020 · American Journal of Hematology
Clinical significance of the lymphocyte-to-monocyte ratio in multiple myeloma patients with negative minimal residual disease: a single-center retrospective analysis
Kazuhito Suzuki, Kaichi Nishiwaki, Riku Nagao, Mitsuji Katori, Ryoko Fukushima, Daiki Hattori, Hidekazu Masuoka, Shingo Yano · 2021 · International Journal of Hematology
The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma
Almuth Maria Anni Merz, Maximilian Merz, Jens Hillengaß, Sarah A. Holstein, Philip L. McCarthy · 2019 · Expert Review of Anticancer Therapy
High-Risk Genetic Multiple Myeloma: From Molecular Classification to Innovative Treatment with Monoclonal Antibodies and T-Cell Redirecting Therapies
Danilo De Novellis, Pasqualina Scala, Valentina Giudice, Carmine Selleri · 2025 · Cells
Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial
María‐Victoria Mateos, Bruno Paiva, María‐Teresa Cedena, Noemí Puig, Anna Maria Sureda, Verónica González‐Calle, Albert Oriol, Enrique M. Ocio, Laura Rosiñol, Yolanda González Montes et al. · 2025 · The Lancet Haematology
Case series: MRD negativity assessment using 11 C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma
Cheong Ngai, Shaji Kunnathu Kumar, Garrett C. L. Ho, Sirong Chen, Chor Sang Chim · 2021 · Therapeutic Advances in Hematology
Role of Patient Characteristics and Insurance Type in Newly Diagnosed Multiple Myeloma Care Disparities
Hamlet Gasoyan, Faiz Anwer, Nicholas J. Casacchia, Jeffrey D. Kovach, Jason Neil Valent, Ming Wang, Michael T. Halpern, Michael B. Rothberg · 2024 · JCO Oncology Practice
Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma
Bhavesh Mohan Lal, Frits van Rhee, Samer Al Hadidi · 2025 · Current Oncology Reports
Delivering intensive therapies to older adults with hematologic malignancies: strategies to personalize care
Rebecca Leah Olin · 2019 · Hematology
Efficacy of daratumumab combination regimen in patients with multiple myeloma: A combined analysis of phase III randomized controlled trials
Thura Win Htut, Kyaw Zin Thein, Alastair Lawrie · 2020 · eJHaem
Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma
Edvan de Queiroz Crusoé, Flávia Cristina Fernandes Pimenta, Ângelo Maiolino, Nelson Siqueira de Castro, Huiling Pei, Damila Cristina Trufelli, Mariana Fernandez, Luciana Barreto Herriot · 2020 · Hematology Transfusion and Cell Therapy
EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma
Sotiris Michaleas, Elisabeth I Penninga, Doris Hovgaard et al. · 2020 · The Oncologist
Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma
Gayathri Ravi, Wilson I. Gonsalves · 2021 · Cancer Treatment and Research Communications
The importance of cytogenetic and molecular aberrations in multiple myeloma
Artur J. Jurczyszyn, Grzegorz Charliński, Anna Suska, David H. Vesole · 2021 · Acta Haematologica Polonica
Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation
Gabriele Buda, Maria Livia Del Giudice, Elisabetta Antonioli, Francesco Ghio, Enrico Orciuolo, Riccardo Morganti, Francesca Martini, Michela Staderini, Sara Galimberti, Mario Petrini · 2021 · Frontiers in Medicine
Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma
Shinichi Mizuno, Chigusa Kitayama, Shigeto Mashiko · 2021 · CEN Case Reports
Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database
Hira S. Mian, Richard LeBlanc, Martha Louzada, Esther Masih‐Khan, Arleigh B. Robertson McCurdy, Christopher Paul Venner, Julie Stakiw, Moustafa Kardjadj, Victor Hugo Jimenez-Zepeda, Michaël Sébag et al. · 2022 · Cancer Medicine
Clinical implications of measurable residual disease assessment in multiple myeloma in the era of quadruplet therapy
Susan Bal, Timothy Martin Schmidt, Luciano J. Costa, Natalie S. Callander · 2022 · Leukemia & lymphoma/Leukemia and lymphoma
Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis
Silvia Mangiacavalli, Claudio Salvatore Cartia, Monica Galli, Sara Pezzatti, Angelo Belotti, Francesca Fazio, Roberto Mina, Magda Marcatti, Anna Maria Cafro, Renato Zambello et al. · 2022 · Haematologica
Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study
Sara Bringhen, Luděk Pour, Reuben Benjamin, Sebastian Grosicki, Chang‐Ki Min, Danielle Leão Cordeiro de Farias, Alexander Vorog, Richard Labotka, Bingxia Wang, Dasha Cherepanov et al. · 2023 · Clinical Lymphoma Myeloma & Leukemia
Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era
Huixing Zhou, Yuan Jian, Juan Du, Junru Liu, Zhiyao Zhang, Guangzhong Yang, Guorong Wang, Ying Tian, Yanchen Li, Yin Wu et al. · 2023 · Cancer Medicine
Mechanisms of resistance to daratumumab in patients with multiple myeloma
Katrine Fladeland Iversen · 2024 · Basic & Clinical Pharmacology & Toxicology
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis
Vânia Hungria, Deborah M. Martinez-Banos, María‐Victoria Mateos, Meletios Athanasios Dimopoulos, Michèle Cavo, Bart M. S. Heeg, Andrea M. Garcia, Annette Lam, Gerardo Machnicki, Jianming He et al. · 2020 · Advances in Therapy
Introduction to “Immunotherapies for Multiple Myeloma”
Massimo Offidani, Maria Teresa Petrucci · 2020 · Pharmaceuticals
Melphalan 200 mg/m2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients
Annamaria Brioli, Felix vom Hofe, Paola Rucci et al. · 2020 · Bone Marrow Transplantation
Characterize, Optimize, and Harmonize: Caring for Older Adults With Hematologic Malignancies
Tanya Marya Wildes, Andrew S. Artz · 2021 · American Society of Clinical Oncology Educational Book
Oncolytic virotherapy – Forging its place in the immunomodulatory paradigm for Multiple Myeloma
Joselle Cook, Aldo A. Acosta‐Medina, Kah Whye Peng · 2021 · Cancer Treatment and Research Communications
Conditioning with melphalan 200 mg/m2 and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care
Gabriel Afram, Roza Chaireti, Katarina Uttervall · 2022 · European Journal Of Haematology
Anti-CD38 antibody for refractory acquired hemophilia A
Wei Liu, Jiaying Liu, Feng Xue, Renchi Yang, Lei Zhang · 2023 · Journal of Thrombosis and Haemostasis
Aiming for the cure in myeloma: Putting our best foot forward
Noffar Bar, Ross Firestone, Saad Z. Usmani · 2023 · Blood Reviews
SOHO State of the Art Updates and Next Questions: Will CAR-T Replace ASCT in NDMM
Eric Matthew Jurgens, Saad Z. Usmani · 2024 · Clinical Lymphoma Myeloma & Leukemia
First‐line therapy with bendamustine/prednisone/bortezomib—A GMMG trial for non‐transplant eligible symptomatic multiple myeloma patients
Wolfgang Ulrich Knauf, Gerrit Dingeldein, Rudolf Schlag et al. · 2020 · European Journal Of Haematology
A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myeloma
Albert Oriol · 2020 · Expert Review of Hematology
Modern Treatments and Future Directions for Relapsed/Refractory Multiple Myeloma Patients
Vikram J. Premkumar, Divaya Bhutani, Suzanne Lentzsch · 2020 · Clinical Lymphoma Myeloma & Leukemia
Initial Therapeutic Approaches to Patients with Multiple Myeloma
Hadi E. Berbari, Shaji Kunnathu Kumar · 2021 · Advances in Therapy
A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients
Enrica Antonia Martino, Giulio Caridà, Danilo Lofaro, A. Bruzzese, Caterina Labanca, Francesco Mendicino, E. Lucia, V. Olivito, Noemi Puccio, Antonino Neri et al. · 2025 · ESMO Open
Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy
Mark B. Meads, Xiaohong Zhao, David R. Noyes, Praneeth Reddy Sudalagunta, Alexandra Achille, Chaomei H. Zhang, Rafael Renatino Canevarolo, Maria João Silva, Dario M. Magaletti, Daniel DeAvila et al. · 2025 · Blood
Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma
Shaji Kunnathu Kumar, Susanna Joan Jacobus, Adam D. Cohen, Matthias Weiss, Natalie S. Callander, Avina Singh, Terri L. Parker, Michael Green, Raymond Thertulien, Benjamin Marshall Parsons et al. · 2026 · New England Journal of Medicine
Immunomodulators in newly diagnosed multiple myeloma: current and future concepts
Michel Delforge, Sophie Vlayen, Nicolas Kint · 2021 · Expert Review of Hematology
Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma
Zahra Goudarzi, Rahil Sadat Shahtaheri, Zhila Najafpour · 2024 · Cost Effectiveness and Resource Allocation
Evaluating the HYDRASHIFT 2/4 Daratumumab assay: a powerful approach to assess treatment response in multiple myeloma
Hyun-Woo Lee, Sangmi Kim, Hyung‐Doo Park · 2024 · Clinical Chemistry and Laboratory Medicine (CCLM)
Response adaptive salvage treatment with daratumumab–lenalidomide–dexamethasone for newly diagnosed transplant‐eligible multiple myeloma patients failing front‐line bortezomib‐based induction therapy—ALLG MM21
Sueh‐li Lim, John Reynolds, Hang Quach · 2024 · British Journal of Haematology
Multiple myeloma and infections in the era of novel treatment modalities
Mobil Akhmedov, Pervin A. Zeynalova, А. А. Феденко · 2024 · Leukemia Research
Corticosteroid therapy in older adults with cancer: Expert recommendations from a task force of the International Society of Geriatric Oncology
Rupert Bartsch, Daniel Aletaha, Thorsten Fuereder, Matti Aapro, François R. Jornayvaz, Pierre Olivier Lang, Denis Migliorini, Chantal Csajka, Marie‐Bernadette Aretin, Tanya M Wildes et al. · 2024 · Journal of Geriatric Oncology
The ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma
Mun Yee Koh, Tae‐Hoon Chung, Nicole Xin Ning Tang, Sabrina Hui Min Toh, Jianbiao Zhou, Tze King Tan, Leilei Chen, Wee Joo Chng, Phaik Ju Teoh · 2024 · Blood
Sustained Improvement in Health‐Related Quality of Life in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient‐Reported Outcomes
Aurore Perrot, Thierry T.F. Facon, Torben Plesner et al. · 2025 · European Journal Of Haematology
Second Primary Malignancies Post Autologous Stem-cell Transplant in Multiple Myeloma from India – Knowing the Unknown
Sumeet Prakash Mirgh, Athira Surendran, Sachin B. Punatar et al. · 2025 · Indian Journal of Hematology and Blood Transfusion
Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions
Paul Gerard Guy Richardson, Elisabeth K. O’Donnell, Peter O’Gorman, Lisa Beatrice Leypoldt, Jacob P. Laubach, Francesca Gay, Xavier P Leleu, Thierry T.F. Facon, Philippe Moreau, Meletios Athanasios Dimopoulos et al. · 2025 · Expert Opinion on Investigational Drugs
Daratumumab and its efficacy in refractory myeloma with anemia
Bhausaheb Pandurang Bagal, Suresh Kumar Bondili, Ravindra Nandhana, Anant Ganesh Gokarn, Avinash Bonda, Manju Sengar · 2020 · Cancer Research Statistics and Treatment
Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma
Sara Ovejero, Jérôme Moreaux · 2021 · Exploration of Targeted Anti-tumor Therapy
Daratumumab and Lenalidomide Maintenance Guided by Minimal Residual Disease in Multiple Myeloma
Binod Dhakal, Saad Z. Usmani · 2021 · The Hematologist
Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
Francesca Fazio, Luca Franceschini, Valeria Tomarchio, Angela Rago, Mariagrazia Garzia, Luca Cupelli, Velia Bongarzoni, Alessandro Andriani, Svitlana Gumenyuk, Agostino Tafuri et al. · 2022 · eJHaem
Patient characteristics, treatment patterns, and outcomes among black and white patients with multiple myeloma initiating daratumumab: A real-world chart review study
Shebli Atrash, Philippe Thompson‐Leduc, Ming‐Hui Tai, Shuchita Kaila, Kathleen S Gray, Isabelle Ghelerter, Marie‐Hélène Lafeuille, David S. Jayabalan, Patrick Lefèbvre, Adriana Rossi · 2022 · Clinical Lymphoma Myeloma & Leukemia
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma
Aimaz Afrough, Leonard C. Alsfeld, Denái R. Milton, Ruby Delgado, Uday Popat, Yago L. Nieto, Partow Kebriaei, Betül Oran, Neeraj Y. Saini, Samer Ali Srour et al. · 2022 · Transplantation and Cellular Therapy
Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice
Makiko Mizuguchi, Yasunobu Okamoto, Hikaru Yagi, Kumiko Kagawa, Etsuko Sekimoto, Hironobu Shibata, Toshio Shigekiyo, Shuji Ozaki · 2023 · International Journal of Hematology
Pomalidomide combinations are a safe and effective option after daratumumab failure
Annamaria Brioli, Laura Gengenbach, Katia Mancuso, Mascha Binder, Thomas Ernst, Florian Heinrich Heidel, Thomas Stauch, Elena Zamagni, Inken Hilgendorf, Andreas Hochhaus et al. · 2023 · Journal of Cancer Research and Clinical Oncology
Spinal lesions in multiple myeloma: Primary bone tumors with distinct prognostic factors
Raphael Ly, Louis‐Marie Terrier, Gabrielle Cognacq, Lotfi Benboubker, Christophe Destrieux, Stéphane Velut, Ilyess Zemmoura, Patrick François, Mourad Aggad, Aymeric Amelot · 2023 · Surgical Oncology
Evidence-based mechanisms of synergy with IMiD agent-based combinations in multiple myeloma
Paola E. Neri, Inger S. Nijhof · 2023 · Critical Reviews in Oncology/Hematology
Autologous stem cell transplantation in patients older than 65 years with multiple myeloma: a real-world study
Cristian Maximiliano Seehaus, Natalia Paola Schutz, Erika Barbara Brulc, Gonzalo Ariel Ferini, Jorge Alberto Arbelbide, Dorotea Beatriz Eugenia Fantl, Ana Lisa Basquiera · 2023 · Hematology Transfusion and Cell Therapy
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
Lisa Beatrice Leypoldt, Maria Gavriatopoulou, Britta Besemer et al. · 2023 · Cancers
Vitamin D and K Supplementation Is Associated with Changes in the Methylation Profile of U266-Multiple Myeloma Cells, Influencing the Proliferative Potential and Resistance to Bortezomib
Karolina Łuczkowska, Piotr Kulig, Bartłomiej Baumert · 2023 · Nutrients
Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse
Peter Michael Voorhees, Vera Jean Suman, Yvonne Adeduni Efebera, Noopur S Raje, Sascha Alexander Tuchman, Cesar Rodriguez Valdes, Jacob P. Laubach, Misty Bova‐Solem, Destin Carlisle, Saad Z. Usmani et al. · 2024 · Blood Advances
Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement
Shweta Deshpande, Morie Abraham Gertz, Angela A. Dispenzieri · 2020 · Leukemia & lymphoma/Leukemia and lymphoma
Maintenance therapy in transplant ineligible adults with newly‐diagnosed multiple myeloma: A systematic review and meta‐analysis
Amaris Karin Balitsky, Aram Karkar, Arleigh B. Robertson McCurdy, Bram N. Rochwerg, Hira S. Mian · 2020 · European Journal Of Haematology
Evolution or revolution in multiple myeloma therapy and the role of the UK
Gordon Cook, Curly T. C. M. Morris · 2020 · British Journal of Haematology
Chimeric Antigen Receptor T Cells for Multiple Myeloma
Andrew J. Cowan, Sherilyn Alvaran Tuazon, Andrew Jay Portuguese, Damian J. Green · 2021 · The Cancer Journal
Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma
Xiaohui Zeng, Qiao Liu, Liubao Peng · 2021 · Advances in Therapy
Monoclonal Antibodies in Myeloma
Monique A. Hartley-Brown, David W. Chitty, Richa Thakur · 2021 · The Cancer Journal
The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma
Meera Mohan, Theresa Camille Maatman, Carolina Schinke · 2021 · Cancers
Evaluation of subcutaneous daratumumab injections in the ambulatory care setting
Andrew H. Tam, Yoonie Jung, Rebecca Young · 2021 · Journal of Oncology Pharmacy Practice
Current and prospective antibody-based therapies in multiple myeloma
Emily Jane Bryer, Christin B. DeStefano, Dickran Gano Kazandjian · 2021 · Seminars in Oncology
Early versus late response to daratumumab-based triplet therapies in patients with multiple myeloma: a pooled analysis of trials POLLUX, CASTOR and MAIA
Jiasheng Wang, Raul Arroyo-Suárez, Srilatha Dasari, Kanithra Sekaran, William W. Tse · 2022 · Leukemia & lymphoma/Leukemia and lymphoma
Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies
Ola Landgren, Dickran Gano Kazandjian, Murielle Roussel, Jagoda K. Jasielec, Dominik Dytfeld, Aparna B. Anderson, Tara Kervin, Karim Saad Iskander, Ian McFadden, Andrzej J. Jakubowiak · 2022 · Leukemia & lymphoma/Leukemia and lymphoma
Use of Resource Modeling to Quantify the Organizational Impact of Subcutaneous Formulations for the Treatment of Oncologic Patients: The Case of Daratumumab in Multiple Myeloma
Carlo Federici, Carla Rognoni, Francesco Costa, Patrizio Armeni, Elisa Crovato, Stefania Bellucci · 2022 · Clinical Therapeutics
Analysis of High-Risk Extramedullary Relapse Factors in Newly Diagnosed MM Patients
Xiaoyan Yue, Donghua He, Gaofeng Zheng, Yang Yang, Xiaoyan Han, Yi Li, Yi Zhao, Wenjun Wu, Qingxiao Chen, Enfang Zhang et al. · 2022 · Cancers
Initial Therapy in Older Patients with Multiple Myeloma
Jacob P. Laubach · 2019 · New England Journal of Medicine
The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma
Arthur Bobin, Hélène Gardeney, Florence Sabirou, Cécile Gruchet, Anthony Lévy, Laly Nsiala, Laura Cailly, Cécile Tomowiak, José Miguel Torregrosa Diaz, Stéphanie Guidez et al. · 2020 · Frontiers in Oncology
Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma
Shuji Ozaki, Hiroshi Handa, Hiromi Koiso, Takayuki Saitoh, Kazutaka Sunami, Tadao Ishida, Kenshi Suzuki, Tomoko Narita, Shinsuke Iida, Yuichi Nakamura et al. · 2021 · Journal of Cancer Research and Clinical Oncology
Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma
Yawara Kawano, Hiroyuki Hata, Seiji Takashio · 2022 · British Journal of Haematology
Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials
Ye Wu, Xia Wu, Xiaoyan Liu, Xue Yan Zheng, Jili Deng, Yuping Gong · 2021 · BMC Cancer
Evolving Paradigms of Therapy for Multiple Myeloma: State of the Art and Future Directions
Scott Ryan Goldsmith, Ravi Vij · 2021 · JCO Oncology Practice
Somatic TP53 Mutations Drive T and NK Cell Dysfunction in AML and Can be Rescued by Reactivating Wild Type p53
Li Li, Muharrem Müftüoğlu, Edward Ayoub, Jiangxing Lv, Mahesh Basyal, Ran Zhao, Prashant S Menon, Aram Bidikian, Po Yee Mak, Yuki Nishida et al. · 2025 · medRxiv
Molecular and immunological determinants of long-term survival in multiple myeloma
Khanmi Kasomva, Kritika Yadav, Siegfried Janz, Binod Dhakal, Sridhar Rao · 2025 · Blood Advances
Choosing the optimal maintenance strategy in multiple myeloma
Benjamin R. Puliafito, Diana D. Cirstea, Noopur S Raje · 2025 · Hematology
Efbalropendekin Alfa enhances human natural killer cell cytotoxicity against tumor cell lines in vitro
Hesham M. Shehata, Pranay Dogra, Sarah Gierke, Patrick G. Holder, Shomyseh Sanjabi · 2024 · Frontiers in Immunology
Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers
Diana Beatriz Bayani, Yihao Clement Lin, Chandramouli Nagarajan, Melissa Gaik Ming Ooi, Allison Ching Yee Tso, John Cairns, Hwee Lin Wee · 2024 · PharmacoEconomics - Open
Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients
Gregorio Barilà, Laura Pavan, Susanna Vedovato, Tamara Berno, Mariella Lo Schirico, Massimiliano Arangio Febbo, Antonella Teramo, Giulia Calabretto, Cristina Vicenzetto, Vanessa Rebecca Gasparini et al. · 2021 · Frontiers in Oncology
Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience
Danilo De Novellis, Raffaele Fontana, Salvatore Palmieri et al. · 2023 · Targeted Oncology
An objective cross-sectional assessment of ChatGPT in hematology-oncology manuscript composition: Balancing promise with factual inaccuracies
Suvir Singh, Pooja Prasad, Kaveri Joshi, Jagdeep Singh, Nitish Garg, Kunal Jain · 2024 · Cancer Research Statistics and Treatment
Comprehensive analysis of serum cytokines in patients with multiple myeloma before and after lenalidomide and dexamethasone
Takuto Tachita, Masaki Ri, Sho Aoki, Arisa T. Asano, Takashi Kanamori, Haruhito Totani, Shiori Kinoshita, Yu Asao, Tomoko Narita, Ayako Masaki et al. · 2024 · Cancer Medicine